Effect of Ocrelizumab on Choroid Plexus Changes in Patients With PPMS

N/AActive Not RecruitingNCT05974852

State University of New York at Buffalo732 enrolled

Overview

The goal of this non-interventional, observational study is to learn if cortical plexus enhancement in patients with primary progressive multiple sclerosis occurs in response to the autoimmune inflammatory process.

To study the effect of ocrelizumab on choroid plexus changes in patients with primary-progressive multiple sclerosis participating in the ORATORIO: a post-hoc analysis of a double-blind, randomized, phase 3, placebo-controlled study

Study Type

OBSERVATIONAL

Enrollment

732

Conditions

Primary Progressive Multiple Sclerosis

Interventions

OcrelizumabOTHER

Non-interventional

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient participating in the ORATORIO study * MRI scans available at baseline * Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 3D T1-WI at baseline Exclusion Criteria: \- None

Locations (1)

Buffalo Neuroimaging Analysis Center

Buffalo, New York, United States

Outcomes

Primary Outcomes

T2 lesion volume

T2 lesion volume as measured using MRI.

Time frame: 5 years

Secondary Outcomes

Changes in choroid plexus

Changes in choroid plexus as measured using MRI.

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.